| Popis: |
In the early 1980s, when fluoroquinolones were an area of rapid development and considerable pharmaceutical company interest, it was commonly believed that resistance to fluoroquinolones would not become a problem, as it had with previous classes of antibiotics, as fluoroquinolone-resistant Escherichia coli could only be selected with great difficulty under laboratory conditions (Smith 1984). The very low minimum inhibitory concentrations (MICs) of these agents for many pathogens, combined with good pharmacokinetics and hence high achievable concentrations at the site of infection, also convinced many that resistance was unlikely to arise in the clinical setting. Furthermore, those mutations which were selected were chromosomally located and recessive to the wild type; thus interspecies spread of resistance alleles was not expected. |
